Recruiting

Observational Study

Sponsor:

Stanford University

Code:

NCT05880797

Conditions

Oropharyngeal Carcinoma

Human Papilloma Virus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to better understand the natural history of oropharyngeal carcinoma (OPC), with or without an association with the human papilloma virus (HPV). For this study, the investigators plan to collect blood from OPC patients prior to treatment and at six subsequent time points.

Conditions

Oropharyngeal Carcinoma

Human Papilloma Virus

Study ID

NCT05880797

Start date

Jul 7, 2023

Status verified date

Sep, 2026

Completion date

Aug, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients diagnosed with oropharyngeal carcinoma or patients with cancer of the unknown primary that is HPV associated, or possibly deemed to be originating from the oropharynx.

Exclusion Criteria:

  • Not willing to sign consent

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Sample collection [ Time Frame: prior to start of treatment ]
  • Sample collection [ Time Frame: up to 36 months post-op ]

Central Contacts and Locations

Central contacts

Nikita Bedi

(650) 723-5957nbedi@stanford.edu

Locations

Stanford University

Recruiting

Palo Alto, California, United States, 94305

Contacts

Nikita Bedi

650-723-5957nbedi@stanford.edu

More Information

Sponsor

Stanford University

Last update posted

Sep 15, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Stanford University on 2026-09-15. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.